問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Surgery

Division of General Internal Medicine

National Taiwan University Hospital

更新時間：2023-09-19

侯明模Hou, Ming-Mo
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

  • m7189@cgmh.org.tw

Recruiting Trial

96Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

侯明模

List

158Cases

2020-04-01 - 2026-05-01

Phase III

Active
An Open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Malignancies

  • Test Drug

    BGB-A317 (Tislelizumab)和BGB-290 (Pamiparib)

Participate Sites
9Sites

Not yet recruiting4Sites

Recruiting3Sites

Terminated2Sites

2024-12-01 - 2031-05-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-12-01 - 2026-07-11

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-12-30 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-07-06 - 2025-05-31

Others

Active
An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

  • Condition/Disease

    Endometrial Neoplasms

  • Test Drug

    Tablets Capsules

Participate Sites
6Sites

Terminated6Sites

2017-08-10 - 2025-01-09

Phase III

Completed
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Patients with unresectable, previously untreated advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

  • Test Drug

    Injection Injection

Participate Sites
12Sites

Recruiting12Sites

2024-06-11 - 2030-12-31

Phase III

Active
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    靜脈點滴注射劑

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2025-09-24 - 2028-11-30

Phase I

Not yet recruiting
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants with Advanced Solid Tumors, Including Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Solid Tumors, Including Hepatocellular Carcinoma

  • Test Drug

    ZW251

Participate Sites
3Sites

Recruiting3Sites

2021-10-01 - 2027-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites

2019-09-01 - 2025-12-31

Phase III

Completed
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma

  • Condition/Disease

    Biliary Tract Carcinoma

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5 6 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB